Small Stocks, Big Money

In our exclusive interview, John Passalacqua, CEO & Director of First Phosphate ($FRSPF | CSE: PHOS), discusses the seismic $94 million all-cash acquisition by Avenir Minerals (Agnico Mines subsidiary) and explains what it signals for the LFP battery supply chain and for First Phosphate.Key topics from the interview include:• Agnico Eagle's $94M all-cash acquisition of Fox River Resources — and what it signals about the strategic value of igneous phosphate.• Why only 2 independent igneous phosphate companies remain in North America, and how First Phosphate stands out with the larger market cap and deposit closest to port.• First Phosphate's exclusive focus on igneous anorthosite phosphate for LFP batteries — and why they avoid sedimentary deposits and carbonatites entirely.• Phosphate comprises ~60% of LFP cathode mass vs. lithium's ~4% — and why Benchmark Minerals ranks it the #2 most critical mineral for the energy transition.• First Phosphate's mine-to-market strategy spanning phosphate rock through purified phosphoric acid, cathode active material, and LFP battery cells.• Project scale: ~255M tonne resource, ~900K tonnes/year concentrate, CAD $2.1B NPV, ~37% IRR, ~3-year payback.👉 First Phosphate is a client of RedChip. Visit https://www.FRSPFinfo.com to learn more and sign up for news alerts.#FRSPF #PHOS #FirstPhosphate #LFPBatteries #BatteryMaterials #CriticalMinerals #EnergyStorage #EVStocks #SmallCapStocks #MicroCapStocks #InvestorInterview

Anixa Biosciences (Nasdaq: ANIX) is advancing a clinical-stage oncology pipeline focused on cancer vaccines and CAR-T therapy, led by its breast cancer vaccine program developed with Cleveland Clinic and supported by U.S. Department of Defense funding.In our exclusive interview, Dr. Amit Kumar, Chairman & CEO of Anixa Biosciences, discusses the company’s breast cancer vaccine targeting alpha-lactalbumin, its completed Phase 1 study, the path toward Phase 2, and the long-term vision of potentially preventing breast cancer before it starts. Dr. Kumar also highlights Anixa’s ovarian cancer CAR-T program, where early clinical data has shown extended survival in certain heavily pretreated patients.Why investors are watching ANIX:• Breast cancer vaccine Phase 1 completed with no major safety concerns reported• 74% protocol-specified immune response reported in Anixa’s investor deck• Phase 2 breast cancer vaccine enrollment listed as an upcoming milestone• Ovarian cancer CAR-T program provides a second clinical-stage opportunity• $14M in cash and short-term investments, no debt, and a clean capital table as of January 31, 2026• Partnerships include Cleveland Clinic, The Wistar Institute, and U.S. Department of Defense supportLearn more about Anixa Biosciences: https://www.redchip.com/stocks/ANIX#ANIX #AnixaBiosciences #BiotechStocks #CancerVaccine #BreastCancer #CART #Oncology #SmallCapStocks #NASDAQ #InvestorInterview #RedChip

In our exclusive interview, Brandon Robinson, Co-Founder, CEO, and Director of New Horizon Aircraft (Nasdaq: HOVR) breaks down why Horizon is taking a different path in advanced air mobility and why investors are starting to pay attention.Horizon’s Cavorite X7 is designed to combine vertical takeoff capability with the speed, range, and economics of a conventional aircraft. The company is targeting performance of about 250 mph, 500-mile range, and up to 1,500 lbs of payload, with operating costs estimated at about $0.97 per seat mile versus roughly $4 to $6 for comparable helicopters. The company has also completed large-scale prototype testing, including vertical takeoff, transition, and forward flight, with a full-scale aircraft currently under construction.For investors, the story is about more than innovation. Horizon is targeting a large installed base of roughly 70,000 helicopters globally, pursuing a capital-efficient OEM model, and positioning itself in high-value mission-critical markets where infrastructure-light aircraft can solve real operational problems. 👉 New Horizon Aircraft is a client of RedChip. Visit https://www.HOVRinfo.com to learn more and sign up for news alerts.#HOVR #HorizonAircraft #eVTOL #AviationStocks #SmallCapStocks #GrowthStocks #Investing #Nasdaq #AirMobility #Aerospace

In our exclusive interview, John Passalacqua, CEO & Director of First Phosphate, explains why First Phosphate ($FRSPF | CSE: PHOS) is positioning itself as a critical North American supplier to the fast-growing LFP battery market.Key topics from the interview include:• A $16.7 million non-dilutive contribution from the Government of Canada, helping advance feasibility work and key process validation without additional equity dilution, according to management.• Why igneous phosphate matters for battery applications, including its high purity and potential efficiency in conversion to battery-grade phosphate for LFP batteries.• First Phosphate’s vertically integrated strategy, spanning phosphate rock, concentrate, purified phosphoric acid, iron phosphate precursor, cathode active material, and LFP battery cells, as shown in the value chain graphic on page 2 of the fact sheet.• Commercial traction, including management commentary on a definitive bankable offtake agreement and prepayment from a European partner.• Scale potential supported by an advanced resource of approximately 255 million tonnes and a Preliminary Economic Assessment highlighting ~900,000 tonnes per year of phosphate concentrate, ~CAD $2.1B NPV, ~37% IRR, and ~3-year payback.• Why management believes phosphate is the overlooked input in LFP batteries, with phosphate representing a major share of cathode mass.👉 First Phosphate is a client of RedChip. Visit https://www.FRSPFinfo.com to learn more and sign up for news alerts.#FRSPF #PHOS #FirstPhosphate #LFPBatteries #BatteryMaterials #CriticalMinerals #EnergyStorage #EVStocks #SmallCapStocks #MicroCapStocks #InvestorInterview

This week's episode of Small Stocks Big Money features exclusive interviews with senior executives from Enlivex Therapeutics Ltd. (NASDAQ: ENLV) & Off The Hook Inc. (NYSE American: OTH)Explore the latest insights and updates in the world of small-cap stocks.Visit RedChip.com to learn more.

In our exclusive interview, Jay Hatfield (Founder, CEO, and Portfolio Manager at InfraCap) outlines a disciplined approach to small-cap investing built around profitability, valuation, and income generation and discusses the opportunity set for small caps as macro conditions evolve.Jay breaks down the portfolio construction behind InfraCap Small Cap Income Fund (NYSE: SCAP), designed to target 7%+ yield by focusing on profitable, dividend-paying companies, selective preferred exposure, and measured options activity.Key topics we covered:• SCAP’s mandate and portfolio filters: why profitability is non-negotiable in small caps• Income-first small caps: combining dividend payers with preferreds and selective call writing• Risk management lessons: avoiding the “blowups” that drive long-term underperformance• Valuation discipline: using PEG / PEGY (growth + yield) to prevent overpaying• Small-cap setup: why undercoverage and depressed relative valuations can create opportunity• Macro watchlist: why core PCE inflation is the key input for Fed policy and small-cap momentumSmall caps remain an under-researched segment of the market. Jay's process emphasizes repeatable underwriting, downside control, and income as a contributor to total return, particularly in environments where rate expectations and inflation data can shift sentiment quickly.#Investing #SmallCaps #IncomeInvesting #Dividends #PreferredStocks #Macro #FederalReserve #SCAPThis post contains sponsored content. This content is for informational purposes only and is not intended to be investment advice. The opinions RedChip expresses are solely their own and are not the opinions of Infrastructure Capital Advisors, LLC, nor its affiliates. The opinions expressed are for information purposes only and do not constitute an offer to buy or sell securities, options, or cryptocurrency. Please conduct your own research and consult your own tax attorney or financial advisor before making an investment decision. The information in this video and the corresponding websites is neither an offer nor a recommendation to buy or sell any security, options on equities, or cryptocurrency. Past performance is not necessarily indicative of future results. No trading strategy is risk-free. Trading and investing involve substantial risk, and you may lose the entire amount of your principal investment or more. You should trade or invest only “risk capital” – money you can afford to lose. ICA has not been involved in the preparation of the content supplied at these websites, and does not endorse these websites, their sponsors, or any of the policies, products, activities, or services offered on the sites. The content is provided, “as is”, without representation or warranty, express or implied, as to their accuracy, completeness, or timeliness of such content, all of which ICA disclaims. This is not financial advice, and returns are not guaranteed. Do your own due diligence before investing.

Watch our replay of Enlivex’s FY25 Financial Results Webcast to hear management discuss the company’s outlook, financial performance, and its differentiated dual strategy combining quality longevity therapeutics with a prediction markets treasury model.Key FY2025 Highlights:• Net income of $1.23 billion• Diluted EPS of $25.48• Total treasury and treasury-related derivative assets of $2.31 billion• Shareholders’ equity of $1.93 billion• $30.0 million in cash, cash equivalents, and short-term investments in digital assetsEnlivex is positioning itself as a public market vehicle with exposure to two high-interest themes:• Quality longevity therapeutics, led by Allocetra™ and its focus on inflammatory conditions associated with aging• Prediction markets infrastructure, through treasury exposure tied to the RAIN protocol👉 Enlivex is a client of RedChip. Visit https://www.ENLVinfo.com to learn more and sign up for news alerts.#ENLV #Enlivex #Nasdaq #SmallCapStocks #MicroCapStocks #BiotechStocks #GrowthStocks #StockMarket #InvestorUpdate #Earnings #HealthcareStocks #Longevity #DigitalAssets

Enlivex (Nasdaq: ENLV) CEO Oren Hershkovitz breaks down the company’s two-pillar strategy designed to build shareholder value through both biotech execution and balance sheet strategy.Pillar 1: Clinical Development (AllocetraTM)Enlivex is advancing its immunotherapy platform with a focus on knee osteoarthritis, a large and growing market with limited effective treatment options. In the interview, management discusses durable, statistically significant results in an older, underserved OA population and the roadmap toward later-stage clinical development.Pillar 2: Digital Asset Treasury Management (Prediction Markets via RAIN)Enlivex is also pursuing a treasury strategy centered on prediction markets, with exposure to the RAIN token. The CEO outlines why the company believes event-driven markets are scaling rapidly, why being an early mover could matter, and how treasury gains and yield could be used to both expand the treasury position and support accelerated clinical development.How the two pillars connectThe core thesis is a dual-engine approach: potential value creation from late-stage clinical catalysts on one side, paired with a treasury strategy intended to generate incremental upside and potentially support funding needs on the other, aiming to reduce reliance on dilution while maintaining momentum in the pipeline.Topics covered:• Why Enlivex believes its two pillars can work together to drive shareholder value• Knee osteoarthritis focus and why age-related patients matter medically and commercially• The RAIN treasury strategy, optionality, and what management sees as the long-term upside• What investors should watch next and the timeline discussed in the interview👉 Enlivex is a client of RedChip. To learn more about ENLV and to read our full disclosure, visit: https://www.ENLVinfo.com#ENLV #SmallCapStocks #BiotechStocks #NASDAQ #Osteoarthritis #ClinicalTrials #InvestorInterview #MicroCapStocks

Off The Hook (NYSE American: OTH) CEO Brian John joins us for an exclusive interview to break down what makes OTH different from a traditional boat dealer and why management believes the company is entering a major growth phase.In our conversation, Brian explains how Off The Hook’s AI-powered platform helps price and move used boats with speed and accuracy, positioning the company as a high-velocity marine liquidity platform in the fragmented U.S. used boat market. The company says it generated approximately $82.6 million in revenue in the first nine months of 2025, delivered about $99 million in FY2024 revenue, and has guided to $140 million to $145 million in FY2026 revenue, excluding the expected impact of the Apex acquisition and post-IPO floorplan expansion.Off The Hook is pitching a differentiated model built around used boat liquidity, vertical integration, and margin capture across sourcing, brokerage, auctions, financing, warranty, and insurance.👉 Off The Hook is a client of RedChip. To learn more about OTH and to read our full disclosure, visit: https://www.redchip.com/stocks/OTH#OTH #OffTheHook #NYSEAmerican #SmallCapStocks #StockMarket #GrowthStocks #InvestorInterview #BrianJohn #BoatingIndustry #AIStocks

What makes Comprehensive Healthcare Systems (OTCQB: CMHSF | TSXV: CHS) a story investors should be watching right now?In our exclusive interview, Chris Cosgrove, President & CEO of Comprehensive Healthcare Systems, breaks down how the company is building a scalable healthcare SaaS platform designed to automate complex benefits administration for unions, self-insured employers, third-party administrators, and government clients.CHS' proprietary Novus 360 platform is built to replace fragmented legacy systems with an integrated solution for eligibility, claims processing, pension administration, compliance, and member engagement. The company is targeting a large U.S. healthcare benefits administration software market estimated at $4B to $6B annually, while already supporting more than 1 million members and processing over $1.8B in healthcare claims.In our interview, Chris discusses:• Why CHS’s position in the government-mandated Taft-Hartley market creates a potential competitive moat• How Novus 360 can automate up to 85% of claims adjudication and improve workflow efficiency• Why the company believes it can scale through both organic growth and acquisitions• Annualized recurring revenue targets of about $10M by year-end 2026, with expected gross margins of 65% to 70% and EBITDA margins of 10% to 15%• The path from approximately US$25M in signed contracts today toward a US$100M contract target by 2028For investors looking at underfollowed healthcare technology and small-cap SaaS opportunities, this interview offers insight into CHS’s strategy, operating leverage potential, and growth roadmap.👉 Comprehensive Healthcare Systems is a client of RedChip. To learn more about CMHSF and to read our full disclosure, visit: https://www.redchip.com/stocks/CMHSF#CMHSF #CHS #OTCQB #TSXV #SmallCapStocks #HealthcareStocks #SaaSStocks #GrowthStocks #StockMarket #Investing #HealthcareTechnology

​  @themetalscompany  (Nasdaq: TMC) is a developer of lower-impact critical metals from seafloor polymetallic nodules, on a dual mission: (1) supply metals for energy, defense, manufacturing and infrastructure with net positive impacts compared to conventional production routes and (2) trace, recover and recycle the metals we supply to help create a metal commons that can be used in perpetuity. The Company has conducted more than a decade of research into the environmental and social impacts of offshore nodule collection and onshore processing. More information is available at www.metals.co.Visit Metals.co to learn more.

BioVie (Nasdaq: BIVI) President and CEO Cuong Do joins us for an exclusive investor interview discussing BioVie’s late-clinical-stage pipeline and upcoming milestones across neurodegeneration and liver disease.In our conversation, Cuong outlines why BioVie is targeting TNFα-mediated inflammation and insulin resistance with bezisterim (formerly NE3107), plus the company’s second program, BIV201, for refractory ascites, a high-mortality complication of liver cirrhosis with no FDA-approved drug therapies today.BioVie is positioning for multiple catalysts across a differentiated clinical-stage portfolio targeting large unmet needs in neurodegeneration and liver disease, supported by an experienced leadership team.Watch the full interview for management’s full roadmap, trial design insights, and how the company is thinking about value creation over the next 12 months.👉 BioVie is a client of RedChip. To learn more about BIVI and to read our full disclosure, visit: https://www.BIVIinfo.com#BIVI #BioVie #BiotechStocks #SmallCapStocks #Investing #Parkinsons #LongCOVID #Alzheimers #ClinicalTrials #HealthcareInvesting

Lithium iron phosphate (LFP) batteries now power the majority of global battery production, but supply chains remain heavily concentrated in Asia. In our exclusive interview, First Phosphate (OTCQX: FRSPF | CSE: PHOS | FSE: KD0) CEO John Passalacqua explains how the company is working to onshore a full North American LFP supply chain, starting with high-purity igneous phosphate in Quebec and progressing downstream toward battery materials.Phosphate is a critical, heavy-by-mass input in LFP cathodes, so securing a North American supply becomes more important as demand grows across energy storage, data centers, and AI infrastructure. First Phosphate highlights its Quebec igneous phosphate as a potential advantage because higher-purity, low-contaminant feedstock can translate into more efficient production of battery-grade purified phosphoric acid versus many sedimentary sources.👉 First Phosphate is a client of RedChip. To learn more about FRSPF and to read our full disclosure, visit: https://www.FRSPFinfo.com#FRSPF #PHOS #BatteryMetals #LFP #EnergyStorage #CriticalMinerals #SmallCapStocks #MicroCapInvesting

In our investor-focused interview, Mark White, CEO of Nexalin Technology (Nasdaq: NXL), breaks down how the company is building a non-invasive neurostimulation platform aimed at major unmet needs across brain health, including depression, insomnia, PTSD/TBI, and Alzheimer’s/dementia.Nexalin’s mission is to lead what it calls the “brain health movement” with treatment designed to be safe, effective, and drug-free, supported by a growing body of peer-reviewed research and a roadmap centered on Mood, Military, and Memory.Nexalin’s edge is its frequency-based approach designed to emulate natural brain activity through Deep Intracranial Frequency Stimulation (DIFS™). Clinical validation includes peer-reviewed results published in Radiology showing improved cognition and stronger brain network connectivity in mild Alzheimer’s disease. Additional peer-reviewed findings point to broader potential, including blood pressure reduction in depression (Journal of Affective Disorders) and improved attention with normalized brain activity in ADHD (Molecular Psychiatry).👉 Nexalin Technology is a client of RedChip. To learn more about NXL and to read our full disclosure, visit: https://www.NXLinfo.com#NXL #Nexalin #Nasdaq #SmallCapStocks #MicroCapStocks #StockMarket #GrowthStocks #BiotechStocks #MedTech #DigitalHealth #MedicalDevices #Neurostimulation

Darren Wang, Founder, Chairman, and CEO of OBOOK Holdings (Nasdaq: OWLS), joins us to discuss how OwlTing is building a compliance-first stablecoin and fiat payment infrastructure for global commerce, as well as what investors should watch in 2026.In our interview, Darren explains why stablecoins are moving beyond speculation into real-world settlement, how OwlPay supports enterprise-scale integrations, and how OWLS is positioning for utilization-driven growth as global payment rails modernize.OWLS is targeting a massive and growing global payments market, with company materials citing global payments revenue above $2.5T in 2024 and projected to exceed $3.0T by 2029, while stablecoins and cross-border settlement are among the fastest-growing segments.👉 OBOOK Holdings is a client of RedChip. To learn more about OWLS and to read our full disclosure, visit: https://www.OWLSinfo.com #Fintech #Stablecoins #Payments #Nasdaq #TechInvesting #OWLS

NioCorp (Nasdaq: NB) CEO Mark Smith joins us to break down a milestone year for the Elk Creek Critical Minerals Project in Nebraska and what could be next for U.S. onshoring of niobium, scandium, and magnetic rare earths.NioCorp is positioning Elk Creek as a construction-ready, fully permitted U.S. critical minerals project with long-duration potential and exposure to national security and next-gen manufacturing demand. Company materials highlight: 75% of planned niobium output under long-term offtake agreements, a DoD Title III grant up to $10M for a domestic scandium mine-to-metal supply chain, and Ex-Im processing of up to ~$780M in potential project financing.👉 NioCorp is a client of RedChip. To learn more about NB and to read our full disclosure, visit: https://www.NioCorpinfo.com #NioCorp #NB #CriticalMinerals #Niobium #Scandium #RareEarths #MiningStocks #MetalsInvesting #EnergyTransition #DefenseTech #SmallCapStocks

Join  @RedChip  for an investor Q&A webinar with ASP Isotopes (Nasdaq: ASPI) Executive Chairman and CEO Paul Mann, covering ASPI’s transition into commercial isotope production and its strategy at the intersection of clean energy, advanced semiconductors, and nuclear medicine.In our session, Paul addresses timelines for revenue-generating isotope shipments, updates on key facilities, capital position, and funding plans, as well as how ASPI’s partnerships could support long-term HALEU demand for next-generation nuclear reactors.ASP Isotopes is advancing proprietary isotope enrichment platforms supporting high-value end markets, including semiconductors (Silicon 28), nuclear medicine (including Yb-176 and other pipeline targets), and clean energy via HALEU supply initiatives. The company highlights definitive agreements with TerraPower for HALEU supply and financing, a joint venture with Fermi America for a U.S. enrichment presence, and a pending acquisition of Renergen to expand into helium and LNG.👉 ASP Isotopes is a client of RedChip. To learn more about ASPI and to read our full disclosure, visit: https://www.ASPIinfo.com #ASPI #Investing #SmallCapStocks #NuclearEnergy #HALEU #SMR #TerraPower #Semiconductors #Isotopes #QuantumComputing #NuclearMedicine #CleanEnergy #EnergyInvesting #TechInvesting

In our in-depth interview, Scott Monteith, CEO of Avalon Advanced Materials (OTCQB: AVLNF), breaks down why Avalon is emerging as one of North America’s most strategically positioned critical minerals companies.🔗 Avalon Advanced Materials is a client of RedChip. To learn more about AVLNF and to read our full disclosure, visit: AVLNFinfo.com.#AVLNF #LithiumStocks #RareEarthStocks #CriticalMinerals #SmallCapStocks #EVSupplyChain #CleanEnergyInvesting #StockInterviews #InvestorEducation

In this exclusive interview, Bruce Ogilvie, Executive Chairman of Alliance Entertainment (NASDAQ: AENT), outlines the company’s strategy to drive sustainable earnings growth across physical media, collectibles, and exclusive licensed content.Alliance Entertainment sits at the center of the global entertainment and collectibles ecosystem, distributing over 340,000 SKUs across vinyl, film, video games, toys, and pop culture collectibles to 35,000+ retail storefronts and 200+ e-commerce platforms. In this discussion, Ogilvie explains how Alliance’s capital-light fulfillment model, deep industry expertise, and exclusive studio relationships are creating durable competitive advantages.Key Topics Covered:• Drivers behind Alliance’s double-digit revenue growth entering fiscal 2026• Expansion of exclusive licensing agreements, including Paramount Home Entertainment• How $250M+ in trailing revenue from exclusive content builds a defensible moat• The strategic importance of Handmade by Robots, Alliance’s proprietary collectibles IP• Margin expansion driven by automation, product mix, and direct-to-consumer fulfillment• Management’s outlook for meaningful EPS growth, with earnings projected to nearly double year over yearWith physical collectibles, vinyl, and premium media formats showing renewed demand, Alliance is leveraging scale, exclusivity, and intellectual property ownership to transition toward higher-margin revenue streams while maintaining strong cash flow and balance sheet discipline.👉 Alliance Entertainment is a client of RedChip. To learn more about AENT and to read our full disclosure, visit: AENTinfo.com.#AENT #AllianceEntertainment #SmallCapStocks #InvestorInterview #StockMarketInvesting #EntertainmentStocks #MediaStocks #CollectiblesMarket #LicensingRevenue #EarningsGrowth #NASDAQStocks #ValueInvesting #GrowthStocks #WallStreet #InstitutionalInvestors #RetailInvestors #PhysicalMedia #VinylRecords #PopCultureCollectibles

In this exclusive interview, David Young, PhD, President of Research & Development and Founder of Processa Pharmaceuticals (Nasdaq: PCSA), breaks down the latest Phase 2 clinical progress for the company’s lead oncology program targeting advanced breast cancer.🔬 Key Topics We Covered:• Positive preliminary Phase 2 data from the oral combination therapy PCS6422 + capecitabine• Evidence showing ~10x increase in cancer-killing metabolites while maintaining similar side effect severity versus standard capecitabine• How Processa’s approach aims to improve efficacy without increasing toxicity• Details on the formal 20-patient interim analysis evaluating safety and efficacy, expected in 2026• How this program could potentially replace current capecitabine monotherapy in certain breast cancer settings• Insights into the FDA development pathway and dose optimization ahead of a potential pivotal trial🎯 David Young brings over 40 years of experience in chemotherapy drug development, including deep expertise in 5-FU and capecitabine metabolism, which uniquely positions him to lead Processa’s clinical innovation.👉 Processa Pharmaceuticals is a client of RedChip. To learn more about PCSA and to read our full disclosure, visit: PCSAinfo.com.#ProcessaPharmaceuticals #PCSA #BiotechStocks #SmallCapStocks #Oncology #BreastCancerResearch #ClinicalTrials #Phase2Trial #CancerTherapeutics #BiotechInvesting #HealthcareStocks #NASDAQStocks #DrugDevelopment #FDAApproval #LifeSciences #GrowthStocks #InvestorInterview

In this exclusive interview, E. Will Gray II, Chairman, CEO, and Interim CFO of New Era Energy & Digital (Nasdaq: NUAI), breaks down the company’s strategy to become a critical player in AI data center infrastructure and power generation.New Era Energy & Digital is developing large scale, powered data center sites in the Permian Basin, leveraging behind the meter natural gas, future nuclear capacity, and renewable energy to meet surging demand from AI, cloud computing, and high performance computing workloads.With global spending on AI infrastructure projected to reach trillions of dollars over the next decade, NUAI is positioning itself at the intersection of energy security and digital transformation.📌 Speed to power, land availability, and cost efficiency are becoming the most critical constraints for AI data center growth. New Era Energy & Digital aims to solve these challenges with scalable, power ready sites in one of the most resource rich regions in the U.S.👉 New Era Energy & Digital is a client of RedChip. To learn more about NUAI and to read our full disclosure, visit: NUAIinfo.com.#NUAI #AIInfrastructure #DataCenters #EnergyStocks #GrowthStocks #AIInvesting #DigitalInfrastructure #InvestorInterview

In our in-depth interview, NioCorp (Nasdaq: NB) CEO Mark Smith discusses the rapidly evolving landscape for U.S. critical minerals and the company’s progress toward construction of its Elk Creek Project in Nebraska. Investors will gain insight into supply chain pressures, heavy rare earth export dynamics, and the rising strategic importance of niobium, scandium, and rare earth elements in defense and clean energy markets.🎯 Key Topics We Covered• Current global constraints impacting U.S. access to heavy rare earths• How investors should evaluate critical mineral projects using feasibility, metallurgy, permitting, and resource validation• Details on NioCorp’s collaboration with Lockheed Martin Skunk Works to advance scandium aluminum alloy technologies• Update on more than $370M raised year to date and progress with the U.S. Export Import Bank on potential project debt financing• Engineering, drilling, and site preparation milestones that position NioCorp for construction readiness📌 Why This Matters for Investors:• NioCorp is advancing one of North America’s largest critical mineral resources with all major permits secured, tier one offtake agreements in place, and growing engagement from defense and industrial end users. The company’s emphasis on feasibility-level engineering, customer-qualified metallurgy, and project financing advancement provides a clearer roadmap toward potential production.Learn more about NioCorp and the Elk Creek Project in our exclusive investor-focused conversation.NioCorp is a client of RedChip. To learn more about NB and to read our full disclosure, visit: NioCorpinfo.com.#NioCorp #NB #CriticalMinerals #RareEarths #Scandium #Niobium #DefenseIndustry #Investing #SmallCapStocks #MiningIndustry #ProjectFinancing

📌 In our exclusive interview, Nova Minerals (Nasdaq: NVA) CEO Chris Gerteisen breaks down the company’s rapid transformation into a U.S. critical minerals and gold development leader. With a $43.4 million Defense Production Act award from the U.S. Department of War, Nova is advancing toward military-grade antimony production by 2026/27 — positioning itself as the first fully integrated domestic supplier in decades.Nova’s Estelle Project in Alaska sits on a 35 km mineralized corridor hosting one of North America’s largest undeveloped gold systems, including a 5.2Moz SK-1300 pit-constrained resource. Chris discusses how the company’s latest world-class drill intercepts support strong project economics and why Nova still trades at a steep valuation discount relative to peers.👉 If you found this interview valuable, make sure to like the video, drop a comment with your thoughts or questions, and subscribe for more in-depth conversations with CEOs from emerging small-cap and microcap companies!Nova Minerals is a client of RedChip. To learn more about NVA and to read our full disclosure, visit: NVAinfo.com.#NovaMinerals #NVA #GoldStocks #CriticalMinerals #Antimony #MiningStocks #SmallCapStocks #GoldInvesting #AlaskaMining #DefenseProductionAct #USCriticalMinerals #GoldExploration

In this exclusive interview, BullFrog AI (Nasdaq: BFRG) CEO Vin Singh discusses how the company’s proprietary bfLEAP™ AI platform and BullFrog Data Networks™ are redefining the economics of drug discovery and development.💡 Key Highlights from the Interview:• Exclusive Data Access: Collaborations with the Lieber Institute for Brain Development and J. Craig Venter Institute provide unmatched datasets driving new discoveries in neuropsychiatric and oncology research.• Commercial Traction: Strategic partnership with Sygnature Discovery enables global sales of BullFrog Data Networks, with up to $30M in projected revenue over 3 years.• Operational Efficiency: Lean model burning just $6M annually while advancing multiple revenue-generating programs.• Clinical Validation: Recent success in a Phase 3 oncology study with Eleison Pharmaceuticals demonstrates the power of BullFrog AI’s technology in optimizing clinical trials.• bfPREP™ Launch: New data preparation module accelerates clinical trial readiness by transforming unstructured data into AI-ready formats in days.Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!Bullfrog AI is a client of RedChip. To learn more about BFRG and to read our full disclosure, visit: BFRGinfo.com.#BFRG #BiotechStocks #AI #DrugDiscovery #ClinicalTrials #Investing #HealthcareInnovation #SmallCapStocks #AIinBiotech

Jackpot Digital (OTCQB: JPOTF | TSXV: JJ) CEO Jake Kalpakian discusses how the company’s flagship Jackpot Blitz® platform is redefining casino poker economics through automation, recurring revenue, and global expansion.💡 Jackpot Digital represents an emerging opportunity at the intersection of technology, automation, and gaming, offering exposure to a rapidly growing segment of the global casino market.Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!Jackpot Digital is a client of RedChip. To learn more about JPOTF and to read our full disclosure, visit: JPOTFinfo.com.#JPOTF #JackpotDigital #SmallCapStocks #GamingStocks #CasinoTechnology #InvestorUpdate #ETG #DigitalGaming #RecurringRevenue #PokerTechnology

🚀 Connect Biopharma (Nasdaq: CNTB) is advancing rademikibart, a next-generation biologic designed to redefine how asthma and COPD are treated — tackling both chronic and acute exacerbations where no biologic currently competes.In this exclusive RedChip Money Report interview, CEO Dr. Barry Quart discusses:✅ How rademikibart targets the IL-4Rα pathway — the same as Dupixent — but with faster onset, superior efficacy, and better safety.✅ The company’s unique positioning in acute exacerbations, a multi-billion-dollar market with no approved biologic therapies.✅ Key upcoming catalysts: topline data from Phase 2 acute studies in 1H 2026 and pharmacology results expected by early next year.✅ CNTB’s strong cash position ($71.8M) and runway into 2027, fully funding its U.S.-focused clinical milestones.✅ How its proven management team — responsible for bringing 16 drugs to FDA approval — is positioning the company for long-term growth.🎬 Watch now to learn why Connect Biopharma could be one of the most compelling small-cap biotech opportunities heading into 2026.Connect Biopharma is a client of RedChip. To learn more about CNTB and to read our full disclosure, visit: CNTBinfo.com.#CNTB #BiotechStocks #SmallCapStocks #AsthmaTreatment #COPD #HealthcareInnovation #Investing #BiotechInvesting #ClinicalTrials #NASDAQ

📊 FatPipe Networks (Nasdaq: FATN) — a pioneer in mission-critical networking and cybersecurity — is driving strong profitability and growth in the multi-billion-dollar SD-WAN and SASE markets.In this exclusive interview, Ragula Bhaskar, PhD, Co-Founder and CEO of FatPipe, discusses:✅ The company’s patented technology and 13 foundational networking patents✅ FatPipe’s 90%+ gross margins and subscription-based model with 36–60 month contracts✅ Channel-first sales strategy through 100+ reseller partners worldwide✅ FY25 financial highlights — $16.3M revenue and $2.0M net income (12.3% margin)✅ Expansion into Southeast Asia and Mexico amid rapid SD-WAN market growth (18.5% CAGR through 2030)💬 “We invented the space, we deliver the best support, and we’re scaling efficiently to grow top and bottom lines,” says Dr. Bhaskar.💡 Why Investors Should Watch:FatPipe operates at the intersection of four large and fast-growing markets — SD-WAN, Cybersecurity, Secure Access Service Edge (SASE), and Network Monitoring — expected to exceed $49B by 2030. The company’s strong IP moat, recurring revenue model, and capital efficiency position it as a rare “Rule of 40” small-cap software company.Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!FatPipe is a client of RedChip. To learn more about FATN and to read our full disclosure, visit: FATNinfo.com.#FATN #SmallCapStocks #Cybersecurity #SDWAN #TechInvesting #Networking #InvestorRelations #SoftwareStocks #Profitability #FinancialNews

💡 60 Degrees Pharmaceuticals (Nasdaq: SXTP) CEO Geoff Dow discusses the company’s mission to tackle infectious diseases with unmet medical needs — and how its FDA-approved malaria drug ARAKODA® (tafenoquine) could soon transform treatment for babesiosis, a growing tick-borne disease with no approved therapies.🚀 Key Highlights:• FDA Breakthrough Therapy Designation request submitted for tafenoquine in babesiosis (Oct 2025)• First patient cured of relapsing babesiosis using tafenoquine-based regimen• Three clinical trials underway, with data expected in 2026 to support a supplementary NDA• $245M peak U.S. market potential and ~$1.1B cumulative revenue opportunity through 2035• Commercial launch underway for ARAKODA® in malaria prevention as travel rebounds📈 Why This Matters for Investors:60 Degrees Pharmaceuticals is one of the smallest Nasdaq-listed biotechs with an FDA-approved product — and it’s pursuing a capital-efficient expansion into a large, underserved infectious disease market. With strong early efficacy signals, a clear regulatory roadmap, and increasing awareness of babesiosis nationwide, SXTP offers investors exposure to a high-upside, low-cost clinical advancement story.🧬 About the Company:60 Degrees Pharmaceuticals (Nasdaq: SXTP) develops and commercializes therapeutics for vector-borne diseases. Its lead product, ARAKODA®, is FDA-approved for malaria prevention and is being advanced into new indications including babesiosis.Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!60 Degrees Pharmaceuticals is a client of RedChip. To learn more about SXTP and to read our full disclosure, visit: SXTPinfo.com.#SXTP #BiotechStocks #FDAApproval #PharmaInvesting #MicroCapStocks #InfectiousDiseases #Babesiosis #MalariaPrevention #HealthcareInnovation #Investors

🔋 Bimergen Energy (OTCQB: BESS) is emerging as a major player in the booming U.S. battery energy storage sector—and CFO Bob Brilon shares how the company is executing on a 2.0 GW pipeline backed by $250 million in equity commitments.With 2GW of BESS assets and a capital-efficient model designed to avoid shareholder dilution, Bimergen is positioned to become a cornerstone in the next generation of U.S. energy infrastructure.🗓️ Construction begins late 2025, operations expected in 2026.Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!Bimergen Energy is a client of RedChip. To learn more about BESS and to read our full disclosure, visit: Bimergeninfo.com.#BESS #BatteryStorage #MicroCapStocks #EnergyStorage #AIInfrastructure #CleanEnergy #Bimergen #Investing #StockMarket #EnergyTransition

Mark White, CEO of Nexalin Technology (Nasdaq: NXL), joins us to discuss how Nexalin aims to simplify and make mental health care more accessible with its at-home “Halo” headset and a digital, physician-monitored model. We cover the latest peer-reviewed study results referenced by the company, the plan for U.S. and international pathways, and what investors should watch next.🎯 What you’ll learn• Nexalin’s vision for easy, drug-free, non-invasive support delivered at home• How the “Halo” headset fits into a virtual care workflow (physician-monitored)• Key takeaways from the company-referenced, peer-reviewed Alzheimer’s study• Commercial model: device + subscription (“razor/razor-blade” economics)• Near-term focus areas: mood/anxiety/sleep, TBI/PTSD, and early dementia• How management thinks about FDA strategy and global expansion🧠 Study reference (as discussed)• Nexalin references a peer-reviewed publication reporting statistically significant cognitive improvements and fMRI-observed connectivity changes in a mild Alzheimer’s cohort using a 40-Hz, 15 mA protocol, with no adverse events reported during the treatment period. 💼 Business model• Clinical setting: device placement with physicians; recurring revenue via single-use disposables/treatments• At-home: headset prescribed/ordered by a physician; subscription to access and remote monitoring via app/cloud• Goal: scale through a digital ecosystem that integrates diagnosis, treatment access, and physician oversight🔎 For investors• Thesis: simplified access, physician-monitored use at home, and recurring revenue economics could unlock a capital-efficient growth path if regulatory and clinical milestones are achieved.• Watchlist catalysts: additional study readouts, regulatory interactions/decisions, progress on U.S. pathway, international indication expansions, commercial pilots/rollouts, and updates on subscription adoption and reimbursement discussions.🔔 Drop your questions for Mark in the comments for future Q&A!Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!Nexalin is a client of RedChip. To learn more about NXL and to read our full disclosure, visit: NXLinfo.com.#Nexalin #NXL #MedTech #DigitalHealth #BrainHealth #Investing #Neurotechnology #Alzheimers #MentalHealth #AtHomeCare

Lantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage biopharmaceutical company redefiningoncology drug development through artificial intelligence. Its proprietary RADR® platform leveragesover 200 billion oncology-specific data points to rapidly identify drug candidates, optimize patienttargeting, and de-risk clinical trials—cutting early development time and cost by up to 70% and 80%,respectively. Lantern’s pipeline includes three clinical-stage assets: LP-300 (Phase 2) for NSCLC innever-smokers, LP-184 (Phase 1) for DDR-deficient solid tumors, and LP-284 (Phase 1) for aggressiveB-cell lymphomas. The company also advances CNS oncology programs via its subsidiary StarlightTherapeutics and is developing novel antibody-drug conjugates (ADCs) in collaboration with globalpartners. With 11 FDA designations, over 100 issued and pending patents, and partnerships spanningJohns Hopkins, MD Anderson, and Bielefeld University, Lantern is positioned to unlock value throughprecision-driven clinical execution and strategic collaborations—all backed by $19.7 million in cash and a lean operating structure.Lantern Pharma is a client of RedChip. Visit LTRNinfo.com to learn more.

Foremost Clean Energy (Nasdaq: FMST) is a rapidly growing North American uranium exploration holding an option to earn up to a 70% interest in 10 underexplored properties from Denison Mines. The portfolio spans over 330,000 acres within a prospective area of the Athabasca Basin surrounded by high-grade deposits. Driven by the resurgent Nuclear Renaissance, Foremost is dedicated to realizing the full potential of its projects, actively exploring in collaboration with Denison. Foremost also has a portfolio of lithium projects at varying stages of development, which are located across 55,000+ acres in Manitoba and Quebec.Foremost Clean Energy is a client of RedChip. Visit www.redchip.com/stocks/fmst to learn more.

Phoenix Motor (OTC: PEVMD) is a pioneer and emerging leader in the electric vehicle (“EV”) industry, designing, building, and integrating electric drive systems and manufacturing heavy-duty transit buses and medium- and light- duty commercial EVs. Phoenix operates two primary brands, PhoenixEV, focused on commercial products including heavy and medium duty EVs (transit buses, shuttle buses, school buses and delivery trucks, among others) and EdisonFuture, which intends to serve international markets, particularly Latin America and Caribbeans region.Phoenix is capitalizing on a robust market opportunity backed by significant federal and state regulatory mandates. With a commanding market share in the transit bus segment and a strategic presence in medium-duty vehicles, Phoenix has established a competitive edge through superior product quality and total cost of ownership. The Company has a base of high-profile customers and boasts a strong order backlog, evidencing substantial market demand, with contracted orders and letters of intent for approximately 250+ units representing $200M in potential revenue. Learn more at phoenixev.ai.PhoenixEV is a client of RedChip. Visit www.redchip.com/stocks/PEVMD to learn more.

60 Degrees Pharmaceuticals (Nasdaq: SXTP) is a growth-oriented biotechnology company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. 60P has successfully achieved regulatory approval of ARAKODA® (tafenoquine), a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline includes development programs for Tafenoquine and Celgosivir targeting fungal, tick-borne, and other viral diseases.60 Degrees Pharmaceuticals is a client of RedChip. Visit www.redchip.com/stocks/SXTP to learn more.

Aptevo Therapeutics Inc. (Nasdaq: APVO) is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies through its proprietary bispecific antibody platforms, ADAPTIR® and ADAPTIR-FLEX®. The company is advancing a diverse pipeline that includes both clinical and preclinical candidates designed to harness the immune system to target hematologic and solid tumors with greater precision and safety. With a focus on innovation, Aptevo is leveraging modular antibody engineering to address areas of high unmet medical need and capture opportunities across multi-billion-dollar oncology markets.Aptevo Therapeutics is a client of RedChip. Visit APVOinfo.com to learn more.

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.Calidi Biotherapeutics is a client of RedChip. Visit www.redchip.com/stocks/cldi to learn more.

Lantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage biopharmaceutical company redefining oncology drug development through artificial intelligence. Its proprietary RADR® platform leverages over 200 billion oncology-specific data points to rapidly identify drug candidates, optimize patient targeting, and de-risk clinical trials—cutting early development time and cost by up to 70% and 80%, respectively. Lantern’s pipeline includes three clinical-stage assets: LP-300 (Phase 2) for NSCLC in never-smokers, LP-184 (Phase 1) for DDR-deficient solid tumors, and LP-284 (Phase 1) for aggressive B-cell lymphomas. The company also advances CNS oncology programs via its subsidiary Starlight Therapeutics and is developing novel antibody-drug conjugates (ADCs) in collaboration with global partners. With 11 FDA designations, over 100 issued and pending patents, and partnerships spanning Johns Hopkins, MD Anderson, and Bielefeld University, Lantern is positioned to unlock value through precision-driven clinical execution and strategic collaborations—all backed by $19.7 million in cash and a lean operating structure.Lantern Pharma is a client of RedChip. Visit RedChip.com to learn more.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company advancing (Z)-endoxifen, a next-generation selective estrogen receptor modulator (SERM) with best-in-class potential across the breast cancer treatment spectrum. The company is strategically prioritizing metastatic breast cancer, where (Z)-endoxifen has shown encouraging clinical activity, favorable tolerability, and potential to address endocrine resistance through dual targeting of ERα and PKCβ1. With multiple Phase 2 trials completed, a proprietary oral formulation, and a strong intellectual property portfolio, Atossa is positioned to deliver meaningful therapeutic innovation and create long-term value for patients and investors alike.Atossa Therapeutics is a client of RedChip. Visit www.redchip.com/stocks/atos to learn more.

Processa Pharmaceuticals (Nasdaq: PCSA) is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa's NGC drugs are modifications of existing FDA-approved oncology therapies, resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa's strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.Processa is a client of RedChip. Visit www.redchip.com/stocks/pcsa to learn more.

Greenwich LifeSciences (Nasdaq: GLSI) is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu (human epidermal growth factor receptor 2) protein, a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or “over-expressor”) levels.Greenwich LifeSciences is a client of RedChip. Visit RedChip.com/stocks/GLSI to learn more.

Fathom Holdings Inc. (Nasdaq: FTHM) is a technology-driven real estate services platform revolutionizing the traditional brokerage model. Through its innovative flat-fee commission structure, proprietary technology, and integrated offerings—spanning residential brokerage, mortgage, title, and SaaS—Fathom enables agents to maximize their earnings while delivering superior scalability and efficiency. With operations across 43 states and a rapidly growing network of over 14,700 agents, Fathom is well-positioned to capitalize on an improving housing market and expand its disruptive, high-margin approach to real estate services.Visit RedChip.com to learn more.

ASP Isotopes is an advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process, to produce and commercialize highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing.ASP Isotopes is a client of RedChip. Visit www.redchip.com/stocks/aspi to learn more.

Enlivex (Nasdaq: ENLV) is a clinical stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages, which are primary immune cells, into their homeostatic state. Osteoarthritis and many other diseases reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra™ has the potential to provide a novel immunotherapeutic mechanism of action and resolution for conditions which are life-threatening and debilitating “unmet medical needs”.Enlivex Therapeutics is a client of RedChip. Visit www.redchip.com/stocks/enlv to learn more.

60 Degrees Pharmaceuticals (Nasdaq: SXTP) is a growth-oriented biotechnology company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. 60P has successfully achieved regulatory approval of ARAKODA® (tafenoquine), a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline includes development programs for Tafenoquine and Celgosivir targeting fungal, tick-borne, and other viral diseases.Visit RedChip.com to learn more.

Foremost Clean Energy Ltd. (Nasdaq: FMST) (CSE: FAT) (WKN: A3DCC8) is a rapidly growing North American uranium and lithium exploration company. The Company holds an option to earn up to a 70% interest in 10 prospective uranium properties (with the exception of the Hatchet Lake, where Foremost is able to earn up to 51%), spanning over 330,000 acres in the prolific, uranium-rich Athabasca Basin region of northern Saskatchewan. As the demand for carbon-free energy continues to accelerate, domestically mined uranium and lithium are poised for dynamic growth, playing an important role in the future of clean energy. Foremost's uranium projects are at different stages of exploration, from grassroots to those with significant historical exploration and drill-ready targets. The Company's mission is to make significant discoveries alongside and in collaboration with Denison through systematic and disciplined exploration programs.Foremost Clean Energy is a client of RedChip. Visit www.redchip.com/stocks/FMST to learn more.

FatPipe, Inc. (Nasdaq: FATN) is a pioneer in secure, software-defined networking technologies that simplify and fortify enterprise connectivity. The company develops and markets enterprise-class software solutions—including Software-Defined Wide Area Networking (SD-WAN), Secure Access Service Edge (SASE), and Network Monitoring Services (NMS)—that enable customers to unify, secure, and optimize their digital infrastructure across cloud, hybrid, and on-premise environments.FatPipe serves over 2,500 end-user customers worldwide across sectors such as government, healthcare, finance, education, and retail, with its largest customer bases in the U.S. and India. The company’s patented technology allows for intelligent traffic failover, enhanced security, simplified network management, and deep observability—all delivered through a flexible, subscription-based model. For the fiscal year ended March 31, 2024, FatPipe generated $17.9 million in revenue and $4.4 million in net income—reflecting a strong 24.4% net margin.FatPipe is a client of RedChip. Visit RedChip.com to learn more.

BioVie (Nasdaq: BIVI) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.BioVie is a client of RedChip. Visit RedChip.com to learn more.

Liberty Star Minerals (OTCQB: LBSR) is a U.S.-based mineral exploration company focused on advancing high-potential copper and gold projects in Arizona’s premier mining districts. The company’s flagship assets include the Red Rock Canyon Gold Project, a rapidly emerging high-grade epithermal gold discovery, and the Hay Mountain Project, a large-scale copper-gold porphyry target with confirmed mineralization. With recent bonanza-grade gold assays at Red Rock Canyon and first-ever drilling validating Hay Mountain’s porphyry potential, Liberty Star is strategically positioned for significant value creation. The company is actively seeking a joint venture partnership to accelerate development while leveraging strong exploration results and a favorable commodities market.Visit www.redchip.com/stocks/lbsr to learn more.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company advancing (Z)-endoxifen, a next-generation selective estrogen receptor modulator (SERM) with best-in-class potential across the breast cancer treatment spectrum. The company is prioritizing metastatic breast cancer, a setting with limited effective therapies and high unmet need, where (Z)-endoxifen has demonstrated encouraging clinical activity and favorable tolerability. This focus may enable a more efficient regulatory pathway while building a foundation for expansion into prevention, neoadjuvant, and adjuvant settings. With multiple ongoing Phase 2 trials, a proprietary oral formulation, and a strong intellectual property portfolio, Atossa is positioned to deliver meaningful therapeutic innovation and create long-term value for patients and investors alike.Visit RedChip.com to learn more.

ConnectM Technology Solutions (Nasdaq: CNTM) is enabling a faster, smarter transition to an all-electric future through its AI-driven energy intelligence platform. The company integrates electrified energy assets with proprietary technology solutions, enabling residential, commercial, and transportation customers to efficiently transition from fossil fuels to renewable energy sources. With 120,000+ connected assets and growing, ConnectM is uniquely positioned in the rapidly expanding $2 trillion electrification market. Operating across Building Electrification, Distributed Energy, and Transportation & Logistics segments, ConnectM provides high-margin, scalable solutions, including AI-powered heat pumps, EV solutions, and smart energy management. Backed by a history of 20 consecutive quarters of revenue growth, a vertically integrated service network, and a first-mover advantage, ConnectM proving that an electrified economy is profitable.ConnectM Technology is a client of RedChip. Visit www.redchip.com/stocks/cntm to learn more.